Contact
searchSearch
HMP Global
Login

Gynecologic Cancer Conference Coverage

News
Patient-Reported Outcomes Show Comparable Quality of Life in Pembrolizumab Plus CCRT for High-Risk, Locally Advanced Cervical Cancer
03/20/2024

Brandon Twyford

Brandon Twyford
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.
The study results underscore the...
03/20/2024
Journal of Clinical Pathways
News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
Brian M. Slomovitz, MD
Conference Coverage
Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer
03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting,...
03/18/2024
Oncology
Conference Coverage
Addition of Induction Chemotherapy to Chemoradiation Improves Survival Outcomes Among Patients with Locally Advanced Cervical Cancer
03/17/2024

Allison Casey

Allison Casey
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.
According to a phase 3 trial,...
03/17/2024
Oncology
David Cibula, MD, PhD
Conference Coverage
Sentinel Lymph Node Biopsy Without Systematic Pelvic Lymphadenectomy is Safe, Effective for Patients With Early-Stage Cervical Cancer
03/17/2024

Featuring David Cibula, MD, PhD

Featuring David Cibula, MD, PhD ...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting,...
03/17/2024
Oncology
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
Conference Coverage
Atezolizumab Plus Bevacizumab and Chemotherapy As New First-Line Treatment Option for Recurrent or Metastatic Cervical Cancer
03/16/2024

Allison Casey

Allison Casey
According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...
According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...
According to results from a...
03/16/2024
Oncology
Conference Coverage
Tisotumab Vedotin Improves Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer
03/16/2024

Amber Denham

Amber Denham
Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...
Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...
Tisotumab vedotin demonstrated a...
03/16/2024
Oncology
Conference Coverage
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States
03/30/2021
03/30/2021
Journal of Clinical Pathways
Conference Coverage
Pembrolizumab and Lenvatinib Use for Endometrial Cancer in Clinical Practice
03/29/2021
03/29/2021
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use